Ezetimibe plus statin combination versus double-dose statin in patients with dyslipidemia and atherosclerotic cardiovascular disease risk: a comprehensive systematic review and meta-analysis of 47 randomized controlled trials

Ezetimibe plus statin therapy demonstrated superior lipid-lowering efficacy compared with double-dose statin therapy, with no additional clinical benefit. There was no difference in overall adverse events. There was a higher incidence of severe adverse events with combination therapy compared to double-dose statin therapy, although these events were rare and not believed to be attributable to medication.

Authors

Institutions

Publication Details

Journal
Baylor University Medical Center Proceedings
Published
2025-04-25
DOI
https://doi.org/10.1080/08998280.2025.2487966
Citations
2
Primary Topic
Lipoproteins and Cardiovascular Health
Type
article
Field-Weighted Citation Impact
4.01
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Ezetimibe plus statin combination versus double-dose statin in patients with dyslipidemia and atherosclerotic cardiovascular disease risk: a comprehensive systematic review and meta-analysis of 47 randomized controlled trials

Yasmine Adel Mohammed, Salem Elshenawy, Yazan Al-Mohtasib, Abdelrahman Mahmoud et al.
2 citations
Baylor University Medical Center Proceedings
Lipoproteins and Cardiovascular Health
4.01
article

Ezetimibe plus statin combination versus double-dose statin in patients with dyslipidemia and atherosclerotic cardiovascular disease risk: a comprehensive systematic review and meta-analysis of 47 randomized controlled trials

Yasmine Adel Mohammed, Salem Elshenawy, Yazan Al-Mohtasib, Abdelrahman Mahmoud, Basel Abdelazeem, Hazem Mohamed Salamah, Majd M. AlBarakat, Ahmed Mazen Amin, Omar Ahmed Abdelwahab, Husam Abu Suilik, Hazem Rezq, Ahmed A. Ibrahim, Ali Ashraf Salah Ahmed, Mohamed R. Abdelraouf
article en
2 citations

Abstract

Ezetimibe plus statin therapy demonstrated superior lipid-lowering efficacy compared with double-dose statin therapy, with no additional clinical benefit. There was no difference in overall adverse events. There was a higher incidence of severe adverse events with combination therapy compared to double-dose statin therapy, although these events were rare and not believed to be attributable to medication.

Baylor University Medical Center ProceedingsVol. 38(4)
West Virginia University (US), Jordan University of Science and Technology (JO), Hashemite University (JO), Mansoura University (EG), Zagazig University (EG), Al-Azhar University (ID), Menoufia University (EG), University of Missouri–Kansas City (US), Alexandria University (EG), Minia University (EG), Assiut University (EG)
Good health and well-being
Openalex Percentile: Top 8%
Lipoproteins and Cardiovascular Health
4.01
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.